Floatz logo

nir178

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Novartis PharmaceuticalsPhase 1Dormant
D
23/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
8/ 100
Competitive Position
89/ 100

Competitive context

230 Active assets in the Metastatic Castration Resistant Prostate Cancer (mCRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
University of California, San Francisco
Phase 4BB

View all 50 →

Same molecule, other indications

nir178 is also rated in:

renal cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →
colorectal cancerDormant
D
Indicative ·
30 / 100
View asset →
triple-negative breast carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →